A groundbreaking analysis conducted by researchers at the Seaver Autism Center for Research and Treatment at Mount Sinai has fundamentally reshaped our understanding of the prevalence of Phelan-McDermid syndrome (PMS), a rare genetic condition often intertwined with autism spectrum disorder. The findings, meticulously detailed in the scientific journal Autism Research, suggest that PMS may be significantly more widespread than previously accounted for, impacting an estimated one individual in every 7,300 people. This revised figure implies that a substantial number of individuals, potentially exceeding 45,000 within the United States alone, may be living with this disorder without a formal diagnosis.
Phelan-McDermid syndrome originates from a specific genetic alteration on chromosome 22, involving a deletion or mutation of the SHANK3 gene. This genetic disruption can manifest in a diverse spectrum of challenges, encompassing intellectual, behavioral, and a range of medical complexities. A striking characteristic of PMS is its high co-occurrence with autism spectrum disorder; indeed, alterations in the SHANK3 gene are now understood to be implicated in as many as one percent of all diagnosed autism cases. The previous underestimation of PMS prevalence highlights a critical gap in diagnostic practices and the accessibility of advanced genetic evaluations, particularly for individuals presenting with developmental and neurodevelopmental differences.
The impetus for this comprehensive reassessment stemmed from a collaborative effort involving numerous stakeholders in the field of genetic diagnostics and autism research. The Mount Sinai team meticulously gathered and analyzed data from a vast cohort, drawing upon the genetic testing results of nearly 180,000 individuals diagnosed with autism. This ambitious undertaking integrated information from a diverse array of sources, including major commercial genetic testing laboratories such as GeneDx, Labcorp, and Ambry Genetics, alongside large-scale research initiatives like the SPARK study and the Autism Sequencing Consortium. Furthermore, data contributed by several prominent children’s hospitals provided crucial clinical context to the genetic findings.
By synthesizing information from these ten distinct datasets, the researchers were able to derive a more accurate prevalence estimate. Their calculations, which carefully considered factors such as undiagnosed individuals, limitations inherent in existing genetic testing methodologies, and individuals with PMS who might not meet the diagnostic criteria for autism, converged on a figure of approximately 13.7 affected individuals per 100,000 people. This translates directly to the aforementioned estimate of one in 7,300, a marked departure from earlier, more conservative projections that often placed the prevalence much lower. The disparity underscores the profound impact of utilizing large, multi-sourced genetic datasets for epidemiological studies.
The significant discrepancy between previously known cases and the newly estimated prevalence is attributed by lead author Tess Levy, MSc, Assistant Professor of Psychiatry at the Icahn School of Medicine at Mount Sinai and a certified genetic counselor at the Seaver Autism Center, to several systemic factors. "The large gap between known and estimated cases is likely due in large part to the fact that many individuals with developmental disabilities and autism are never offered genetic testing," stated Dr. Levy. She further elaborated that families may encounter significant financial hurdles, such as insurance barriers, or may undergo genetic tests that are not sufficiently sensitive to detect the specific genetic alterations affecting the SHANK3 gene. This highlights a critical need for broader and more equitable access to comprehensive genetic diagnostic tools.
The implications of this research extend far beyond epidemiological statistics, emphasizing the transformative potential of widespread genetic testing. The researchers advocate for a paradigm shift wherein genetic evaluation becomes a routine component of the diagnostic process for all children identified with autism. "We recommend that every child with autism undergo genetic testing, because knowledge is power," asserted Joseph D. Buxbaum, PhD, Director of the Seaver Autism Center and senior author of the study. Dr. Buxbaum, also a co-founder of the Autism Sequencing Consortium, explained that "These genetic findings allow researchers to design more targeted clinical trials for potential therapies." He expressed optimism about the future, believing that "within the next five years, we’ll see successful examples of new treatments coming from these genetic discoveries."
This comprehensive study, supported by the dedicated efforts of CureSHANK and Neuren Pharmaceuticals, represents one of the most extensive attempts to date to quantify the true prevalence of Phelan-McDermid syndrome. The proactive engagement of Neuren Pharmaceuticals in initiating this landmark study, in collaboration with the Seaver Autism Center and CureSHANK, was driven by the pressing need to identify individuals with PMS as novel therapeutic interventions move closer to clinical application. Rachel Groth, PhD, Head of External Innovation and Patient Advocacy at Neuren Pharmaceuticals, articulated this imperative: "Neuren Pharmaceuticals initiated this landmark PMS prevalence study in collaboration with the Seaver Autism Center at Mount Sinai and CureSHANK because, with new treatments moving closer to reality, identifying these individuals has become an ethical imperative. Patients cannot benefit from these advances if they never receive a diagnosis."
The timing of these findings is particularly significant given the accelerating pace of research and development in the therapeutic landscape for Phelan-McDermid syndrome. Several promising clinical trials are currently underway, many of which are exploring precision medicine approaches designed to directly address the underlying biological mechanisms of the disorder. For individuals diagnosed with PMS and their families, receiving a definitive genetic diagnosis now signifies more than just an explanation for their symptoms; it can unlock pathways to specialized medical care, participation in cutting-edge research studies, access to vital clinical trials, enrollment in supportive patient networks, and, critically, the potential to benefit from disease-modifying treatments.
Geraldine Bliss, Board Chair of CureSHANK, echoed the sentiment of many within the patient advocacy community, stating, "This study confirms what many families, clinicians, and advocates have suspected for years." She emphasized the widespread nature of the issue, noting, "There are likely tens of thousands of individuals with Phelan-McDermid syndrome who have never received a genetic diagnosis." She further underscored the urgency of diagnostic identification in light of therapeutic advancements: "At a time when multiple therapeutics are advancing into clinical trials, finding these individuals has never been more important."
The outcomes of this research also serve to bolster the ongoing advocacy efforts by CureSHANK to broaden access to genetic testing and to champion the goals of initiatives like Start Genetic. This global awareness campaign aims to instill a "genetic first" mindset among patients, their families, healthcare providers, and advocacy organizations, encouraging a proactive approach to genetic evaluation. Ultimately, the overarching message conveyed by these findings is that the remarkable progress being made in the field of precision medicine can only achieve its full potential to impact patient lives if individuals are first accurately identified and formally diagnosed with their respective genetic conditions.
About the Author
